Skip to main content
. 2022 Aug 15;10(8):1973. doi: 10.3390/biomedicines10081973

Table 3.

Univariate and multivariate analysis for progression-free survival in the entire study population.

Covariates B SE p-Value HR (95% CI)
Univariate analysis
Age −0.006 0.014 0.651 0.99 (0.96–1.02)
Female gender −0.500 0.257 0.025 0.60 (0.36–1.01)
Time from onset to diagnosis −0.005 0.004 0.225 0.99 (0.98–1.01)
Diagnosis of FPF 0.990 0.310 0.005 2.69 (1.2–6.3)
FVC > 70% −0.392 0.242 0.030 0.67 (0.32–0.97)
DLCO > 50% −0.159 0.279 0.568 0.85 (0.49–1.47)
paO2/FiO2 > 300 −0.719 0.455 0.114 0.48 (0.20–1.18)
SpO2 > 90% during 6MWT −0.178 0.364 0.625 0.83 (0.41–1.70)
UIP pattern at HRCT 0.115 0.195 0.277 1.2 (0.72–1.65)
Multivariate analysis
Age −0.005 0.017 0.778 0.99 (0.96–1.02)
Female gender −0.494 0.312 0.113 0.61 (0.33–1.12)
FVC > 70% −0.361 0.266 0.175 0.63 (0.34–1.34)
Diagnosis of FPF 1.234 0.588 0.036 3.43 (1.08–10.87)

6MWT: 6-min walking test; DLCO: diffusion lung capacity for carbon monoxide; FiO2: fraction of inspired oxygen; FVC: forced vital capacity; HRCT: high resolution computed tomography; FPF: familial pulmonary fibrosis; paO2: arterial partial pressure of oxygen; SpO2: peripheral oxygen saturation; UIP: usual interstitial pneumonia.